Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2013-01-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 7 pages 171.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'December 2012 Quarterly update and Appendix 4C' and contains detailed financial data including consolidated cash flow statements, payments to directors, financing facilities, and compliance statements. The presence of the Appendix 4C form, which is a recognized quarterly report format for entities admitted on the basis of commitments, confirms this is a quarterly financial report. The document length is 8751 characters, which is substantial and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2013
2013-01-30 English
Change of Director's Interest Notice 2 pages 38.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of securities held before and after the change, nature of the interest, and transaction details. This is a report of personal share transactions by a company director. The document length is 3089 characters, which is typical for such notices. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2013-01-24 English
Update and Status review of HI-164 therapy for COPD 2 pages 58.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 January 2013, providing an update and status review of a clinical therapy (HI-164) for COPD. It discusses possession of clinical study data, preliminary analysis, and future development plans. The document is relatively short (3871 characters) and does not contain financial statements, detailed financial performance, or regulatory certifications. It is an announcement of clinical trial data and strategic review rather than a full report or financial filing. There is no indication of it being an earnings release, annual report, or management discussion. The content fits best as a general regulatory announcement to the market about clinical development progress and strategic considerations. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2013-01-20 English
Change of Director's Interest Notice 3 pages 57.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of securities held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is 3452 characters, which is consistent with a detailed notice rather than a full financial report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2013-01-10 English
Becoming a substantial holder 2 pages 43.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001, titled 'Notice of initial substantial holder.' It details the substantial shareholding of Octa Phillip Asset Management Ltd in Probiomics, including voting power, nature of relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding event, specifically the acquisition of a substantial interest in the company. It is not a financial report, management announcement, or other types of filings such as earnings releases or AGM materials. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or reference to another report.
2012-04-03 English
New Australian Drug Developer Lists on ASX 5 pages 95.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the relisting of a company on the Australian Securities Exchange (ASX) following a reverse takeover. It includes information about the company's business strategy, clinical trial progress, shareholder structure, management team, and market positioning. The document is dated April 4, 2012, and provides extensive background on the company, its drug development pipeline, and the market opportunity. It does not contain financial statements, audit opinions, or detailed financial results. It is not a transcript of a call, nor a regulatory filing or certification. The content is consistent with a Capital/Financing Update (CAP) as it discusses the company's relisting, capital raising, shareholder base, and financing status. The length (9276 characters) and detail support this classification rather than a brief announcement or a full annual/interim report.
2012-04-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.